Merck takes Terns
After reporting stellar data at ASH, Terns is acquired for $6.7bn.
BeOne looks to a degrader combo
Pivotal trials of sonrotoclax plus the group’s BTK degrader are set to start soon.
Karyopharm gets an Xpovio blow
The Sentry trial hits on spleen volume reduction, but misses on symptoms.
Boehringer takes Imdelltra rival straight to first line
Dareon-Lung-1 will test obrixtamig plus Tecentriq and chemo in small-cell lung cancer.
Cell therapies head for the clinic
Clinical trial entrants include projects from Gyala, Beijing Biotech and Neowise.
Gilead puts its Car-T money where its mouth is
KITE-753 is to enter pivotal development – head-to-head against Yescarta.
Pan-KRAS gets even more crowded
Projects from Chia Tai and Kestrel enter phase 1, along with a bispecific Kelun ADC.
AACR 2026 – private biotechs score plenaries
Circle Pharma and Verismo feature in coveted sessions.
